Bliss Gvs Pharma Limited (BLISSGVS) AI Stock Analysis

Bliss Gvs Pharma Limited

(NSE:BLISSGVS)

Select Model

Rating:77Outperform

Price Target:INR 736.00▲(19.25% Upside)

Action:reiterated

Date:08/20/26

The stock earns a solid score driven primarily by a very strong, low-leverage balance sheet and improving profitability, reinforced by robust upward price momentum, while an expensive valuation and overbought technical readings limit upside and keep the overall rating below the highest tier.

Positive Factors

Revenue GrowthSteady multi-year revenue growth indicates continued demand for the company’s medicines across its domestic and international markets. A growing revenue base can support scale benefits, broader product adoption, and sustained investment in women’s health and other therapeutic areas over the next several quarters.

Negative Factors

Volatile Profit MarginsHistorical margin volatility makes future earnings power less predictable than the revenue trend alone suggests. Repeated fluctuations could limit the consistency of returns and reduce management’s ability to plan reinvestment, especially if another period of weaker profitability emerges.

Bliss Gvs Pharma Limited (BLISSGVS) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 68.85B
Dividend Yield: 0.23%
Average Volume (3M): 21.61K
Price to Earnings (P/E): 50.7
Beta (1Y): 1.03
Revenue Growth: 20.59%
EPS Growth: 27.16%
Country: India
Employees: 1,033
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Bliss Gvs Pharma Limited Business Overview & Revenue Model

Company Description

Established in 1984 and headquartered in Mumbai, India, Bliss GVS Pharma Limited specializes in the development, manufacturing, and distribution of a comprehensive array of pharmaceutical products. The company's pharmaceutical portfolio includes an e...

Bliss Gvs Pharma Limited Financial Statement Overview

Summary

Overall financial profile is strong: revenue and profit have improved after a weak 2022, margins are generally healthy, the balance sheet is very conservative with rising equity and sharply reduced debt, and cash flows broadly support earnings despite some volatility.

Income Statement

78Positive

Balance Sheet

88Very Positive

Cash Flow

72Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	10.05B	9.27B	8.10B	7.66B	7.47B	7.38B
Gross Profit	4.63B	5.02B	3.96B	2.49B	3.50B	3.47B
EBITDA	2.35B	2.35B	1.27B	1.49B	1.35B	762.38M
Net Income	1.36B	1.29B	842.99M	754.54M	708.59M	150.40M
Balance Sheet
Total Assets	0	14.92B	13.01B	12.14B	11.57B	11.09B
Cash, Cash Equivalents and Short-Term Investments	1.89B	1.89B	1.41B	1.41B	684.11M	1.35B
Total Debt	0	217.50M	881.04M	998.40M	1.02B	1.09B
Total Liabilities	-12.32B	2.61B	2.09B	2.11B	2.39B	2.62B
Stockholders Equity	12.32B	11.93B	10.50B	9.67B	8.84B	8.19B
Cash Flow
Free Cash Flow	483.04M	818.87M	298.48M	1.24B	-594.86M	614.77M
Operating Cash Flow	775.52M	1.39B	1.06B	1.52B	343.13M	1.35B
Investing Cash Flow	-272.20M	-382.80M	-754.41M	-1.33B	-77.51M	-929.75M
Financing Cash Flow	-448.06M	-892.11M	-303.45M	-208.93M	-249.38M	-237.30M

Bliss Gvs Pharma Limited Technical Analysis

Technical Analysis SentimentPositive

Last Price617.20

Price Trends

50DMA654.32Negative

100DMA569.88Positive

200DMA406.46Positive

Market Momentum

MACD-2.56Positive

RSI49.15Neutral

STOCH75.98Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLISSGVS, the sentiment is Positive. The current price of 617.20 is below the 20-day moving average (MA) of 653.98, below the 50-day MA of 654.32, and above the 200-day MA of 406.46, indicating a neutral trend. The MACD of -2.56 indicates Positive momentum. The RSI at 49.15 is Neutral, neither overbought nor oversold. The STOCH value of 75.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BLISSGVS.

Bliss Gvs Pharma Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:BLISSGVS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:BLISSGVS	77Outperform	INR 68.94B	50.66	―	0.23%	20.59%	27.16%
IN:IOLCP	72Outperform	INR 52.17B	31.06	―	0.56%	18.56%	60.06%
IN:INNOVACAP	63Neutral	INR 59.00B	38.10	―	0.19%	34.47%	20.42%
IN:RPGLIFE	62Neutral	INR 42.54B	35.60	―	0.93%	11.78%	-34.54%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:ORCHPHARMA	54Neutral	INR 49.89B	489.15	―	―	10.83%	-89.83%
IN:UNICHEMLAB	51Neutral	INR 34.04B	11.17	―	―	9.43%	132.94%

* General Sector Average

Performance Comparison

IN:BLISSGVS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:BLISSGVS	Bliss Gvs Pharma Limited	648.40	494.04	320.05%
IN:INNOVACAP	Innova Captab Limited	1031.10	221.75	27.40%
IN:IOLCP	IOL Chemicals & Pharmaceuticals Ltd.	177.75	84.69	91.01%
IN:ORCHPHARMA	Orchid Pharma Limited	833.05	64.40	8.38%
IN:RPGLIFE	RPG Life Sciences Limited	2572.40	160.58	6.66%
IN:UNICHEMLAB	Unichem Laboratories Limited	483.45	9.00	1.90%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 20, 2026

Bliss Gvs Pharma Limited AI Stock Analysis